Kamada (NASDAQ:KMDA) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Kamada (NASDAQ:KMDA) released its quarterly earnings results on Monday. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.13 by $0.01, FiscalAI reports. The firm had revenue of $52.03 million for the quarter, compared to the consensus estimate of $52.51 million. Kamada had a return on equity of 8.37% and a net margin of 11.60%.

Kamada Price Performance

NASDAQ KMDA opened at $7.23 on Monday. Kamada has a twelve month low of $6.55 and a twelve month high of $9.35. The business has a 50-day moving average price of $8.08 and a 200-day moving average price of $8.00. The firm has a market cap of $415.80 million, a price-to-earnings ratio of 19.03, a price-to-earnings-growth ratio of 0.61 and a beta of 0.90.

Kamada Cuts Dividend

The firm also recently disclosed an annual dividend, which was paid on Thursday, September 17th. Stockholders of record on Thursday, August 27th were paid a $0.17 dividend. This represents a dividend yield of 206.0%. This is a negative change from Kamada’s previous annual dividend of $0.25. The ex-dividend date of this dividend was Thursday, August 27th. Kamada’s dividend payout ratio is currently 34.21%.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on KMDA. Benchmark reiterated a “buy” rating on shares of Kamada in a research report on Tuesday, July 21st. UBS Group reissued a “buy” rating and issued a $15.00 target price on shares of Kamada in a research report on Friday, September 18th. Weiss Ratings raised Kamada from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday, October 9th. William Blair set a $15.00 price target on Kamada in a research note on Tuesday, July 21st. Finally, Wall Street Zen raised shares of Kamada from a “hold” rating to a “strong-buy” rating in a research report on Saturday, August 15th. Four analysts have rated the stock with a Buy rating. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $13.50.

About Kamada

Kamada Ltd. is a biopharmaceutical company focused on the development, manufacturing and commercialization of plasma-derived therapeutics and specialty pharmaceutical products. The company uses its expertise in plasma protein purification to address rare diseases, immune deficiencies and other serious medical conditions.

Kamada’s portfolio includes GLASSIA, an intravenous alpha-1 antitrypsin therapy used as augmentation treatment for adults with severe alpha-1 antitrypsin deficiency and emphysema.